Výsledky vyhledávání

Akademický článek

Feasibility and Tolerability of Adjuvant Capecitabine-Based Chemoradiation in Patients With Breast Cancer and Residual Disease After Neoadjuvant Chemotherapy: A Prospective Clinical Trial.

Autor: Balbach ML; Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee., Sherry AD; Department of Radiation Oncology, Division of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Rexer BN; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Abramson VG; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Niermann KJ; Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee., Johnson CR; Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee., Park BH; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Mayer IA; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Chakravarthy AB; Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address: bapsi.chak@vumc.org.

Publikováno v: International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2024 Apr 01; Vol. 118 (5), pp. 1262-1270. Date of Electronic Publication: 2023 Jul 16.

Zobrazit plný text záznamu

Akademický článek

Obesity and metabolic syndrome are associated with short-term endocrine therapy resistance in early ER + breast cancer.

Autor: Bergman R; Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA., Berko YA; Meharry Medical College, Nashville, TN, USA.; Currently Piedmont Newnan Hospital, Newnan, Georgia., Sanchez V; Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA., Sanders ME; Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA., Gonzalez-Ericsson PI; Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA., Arteaga CL; Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.; UTSW Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, USA., Rexer BN; Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA. Brent.rexer@vumc.org.; Division of Hematology/Oncology, Vanderbilt University Medical Center, 2220 Pierce Ave, Nashville, TN 777 PRB 37232-6307, USA. Brent.rexer@vumc.org.

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2023 Jan; Vol. 197 (2), pp. 307-317. Date of Electronic Publication: 2022 Nov 17.

Zobrazit plný text záznamu

Akademický článek

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.

Autor: Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Beeram M; South Texas Accelerated Research Therapeutics, San Antonio, TX, United States., Beck JT; Department of Medical Oncology and Hematology, Highlands Oncology, Springdale, AR, United States., Conlin A; Providence Cancer Center, Portland, OR, United States., Dees EC; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States., Puhalla SL; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, United States., Rexer BN; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States., Burris HA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, United States., Jhaveri K; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.; Department of Medicine, Weil Cornell Medical College, New York, NY, United States., Helsten T; Moores Cancer Center, University of California San Diego, San Diego, CA, United States., Becerra C; Texas Oncology, Dallas, TX, United States., Kalinsky K; Department of Medicine, Columbia University, New York, NY, United States.; Department of Hematology/Oncology, Emory University Winship Cancer Institute, Atlanta, GA, United States., Moore KN; Stevenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.; Sarah Cannon Research Institute, Nashville, TN, United States., Manuel AM; Eli Lilly and Company, Indianapolis, IN, United States., Lithio A; Eli Lilly and Company, Indianapolis, IN, United States., Price GL; Eli Lilly and Company, Indianapolis, IN, United States., Chapman SC; Eli Lilly and Company, Indianapolis, IN, United States., Litchfield LM; Eli Lilly and Company, Indianapolis, IN, United States., Goetz MP; Department of Oncology, Mayo Clinic, Rochester, MN, United States.; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, United States.

Publikováno v: Frontiers in oncology [Front Oncol] 2022 Feb 10; Vol. 11, pp. 810023. Date of Electronic Publication: 2022 Feb 10 (Print Publication: 2021).

Zobrazit plný text záznamu

Akademický článek

Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer.

Autor: Axelrod ML; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Nixon MJ; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Gonzalez-Ericsson PI; Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville, Tennessee., Bergman RE; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Pilkinton MA; Department of Infectious Disease, Vanderbilt University Medical Center, Nashville, Tennessee., McDonnell WJ; Department of Infectious Disease, Vanderbilt University Medical Center, Nashville, Tennessee., Sanchez V; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.; Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville, Tennessee., Opalenik SR; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Loi S; Department of Oncology, University of Melbourne and Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Zhou J; IsoPlexis Corporation, Branford, Connecticut., Mackay S; IsoPlexis Corporation, Branford, Connecticut., Rexer BN; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Abramson VG; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Jansen VM; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Mallal S; Department of Infectious Disease, Vanderbilt University Medical Center, Nashville, Tennessee., Donaldson J; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Krop IE; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Garrido-Castro AC; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Marotti JD; Department of Pathology & Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.; Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire., Shee K; Department of Molecular & Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire., Miller TW; Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.; Department of Molecular & Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire., Sanders ME; Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville, Tennessee.; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee., Mayer IA; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.; Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville, Tennessee., Salgado R; Department of Oncology, University of Melbourne and Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium., Balko JM; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. justin.balko@vumc.org.; Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville, Tennessee.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Nov 01; Vol. 26 (21), pp. 5668-5681. Date of Electronic Publication: 2020 Aug 21.

Zobrazit plný text záznamu

Akademický článek

Combining Adjuvant Radiotherapy With Capecitabine in Chemotherapy-resistant Breast Cancer: Feasibility, Safety, and Toxicity.

Autor: Sherry AD; Vanderbilt University School of Medicine, Nashville, TN., Mayer IA; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN., Ayala-Peacock DN; Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN., Abramson VG; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN., Rexer BN; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN., Chakravarthy AB; Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN. Electronic address: bapsi.chak@vumc.org.

Publikováno v: Clinical breast cancer [Clin Breast Cancer] 2020 Aug; Vol. 20 (4), pp. 344-352.e1. Date of Electronic Publication: 2020 Mar 06.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání